Przemysław Zaręba, Anna K Drabczyk, Jolanta Jaśkowska, Grzegorz Satała
In the pharmacotherapy of schizophrenia, there is a lack of effective drugs, and currently used agents cause a large number of side effects. The D2 , 5-HT1A , 5-HT2A receptors are among the most important receptor targets in the treatment of schizophrenia, but antagonism at 5-HT6 and 5-HT7 receptors may bring about additional improvement of cognitive functions. However, doubt exists regarding the importance of 5-HT7 R in the pharmacotherapy. In 2010, lurasidone (with high affinity for D2 , D3 , 5-HT1A , 5-HT2A , 5-HT7 receptors) was approved for the treatment of schizophrenia...
May 15, 2020: Bioorganic & Medicinal Chemistry